Advances in kinase targeting: Current clinical use and clinical trials

Trends in Pharmacological Sciences

Volumn 35, Issue 11, 2014, Pages 604-620

  Rask Andersen, Mathias ^a   Zhang, Jin ^a,b   Fabbro, Doriano ^c   Schiöth, Helgi B ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

^c Piqur Therapeutics AG   (Switzerland)

Author keywords

clinical trials; drug targets; phosphotransferase; protein kinase; serine threonine protein kinase; tyrosine protein kinase

Indexed keywords

AFATINIB; ANTIINFLAMMATORY AGENT; AXITINIB; BOSUTINIB; CABOZANTINIB; CETUXIMAB; CRIZOTINIB; DABRAFENIB; DASATINIB; ERLOTINIB; GEFITINIB; IBRUTINIB; IMATINIB; LAPATINIB; NILOTINIB; PAZOPANIB; PHOSPHOTRANSFERASE; PONATINIB; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; REGORAFENIB; RUXOLITINIB; SORAFENIB; SOTATERCEPT; SUNITINIB; TRAMETINIB; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB; VEMURAFENIB; ENZYME ACTIVATOR;

AGE RELATED MACULAR DEGENERATION; ALZHEIMER DISEASE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; DIABETIC FOOT; DIABETIC RETINOPATHY; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG USE; ENZYME INHIBITION; ERYTHROPOIESIS; GLAUCOMA; HEARING IMPAIRMENT; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NEUROPATHIC PAIN; OSTEOLYSIS; OSTEOPOROSIS; PARKINSON DISEASE; PROTEIN TARGETING; REVIEW; TREATMENT INDICATION; WOUND HEALING IMPAIRMENT; ANIMAL; CLINICAL TRIAL (TOPIC); METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANIMALS; CLINICAL TRIALS AS TOPIC; ENZYME ACTIVATORS; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTEIN KINASES;

EID: 84908371590     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2014.09.007     Document Type: Review

References (108)

1. M. Rask-Andersen Evaluation of the targets for drugs in clinical trials suggests major shift in molecular class and indication Annu. Rev. Tox. Pharm. 54 2014 9 26
2. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
3. I. Hers Akt signalling in health and disease Cell. Signal. 23 2011 1515 1527
4. P. Geraldes, and G.L. King Activation of protein kinase C isoforms and its impact on diabetic complications Circ. Res. 106 2010 1319 1331
5. E.K. Kim, and E.J. Choi Pathological roles of MAPK signaling pathways in human diseases Biochim. Biophys. Acta 1802 2010 396 405
6. J. Bove Fighting neurodegeneration with rapamycin: mechanistic insights Nat. Rev. Neurosci. 12 2011 437 452
7. I.B. McInnes, and G. Schett The pathogenesis of rheumatoid arthritis N. Engl. J. Med. 365 2011 2205 2219
8. M. Rask-Andersen Trends in the exploitation of novel drug targets Nat. Rev. Drug Discov. 10 2011 579 590
9. C. Knox DrugBank 3.0: a comprehensive resource for 'omics' research on drugs Nucleic Acids Res. 39 2011 D1035 D1041
10. UniProt Consortium Update on activities at the Universal Protein Resource (UniProt) in 2013 Nucleic Acids Res. 41 2013 D43 D47
11. G. Manning The protein kinase complement of the human genome Science 298 2002 1912 1934
12. UniProt Consortium Reorganizing the protein space at the Universal Protein Resource (UniProt) Nucleic Acids Res. 40 2012 D71 D75
13. J. Boudeau Emerging roles of pseudokinases Trends Cell Biol. 16 2006 443 452
14. N. Kannan, and S.S. Taylor Rethinking pseudokinases Cell 133 2008 204 205
15. D.R. Robinson The protein tyrosine kinase family of the human genome Oncogene 19 2000 5548 5557
16. R. Capdeville Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug Nat. Rev. Drug Discov. 1 2002 493 502
17. J. Zhang Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 9 2009 28 39
18. M.A. Fabian A small molecule-kinase interaction map for clinical kinase inhibitors Nat. Biotechnol. 23 2005 329 336
19. M.W. Karaman A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 26 2008 127 132
20. S.J. Mandl Immunotherapy with MVA-BN(R)-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells Cancer Immunol. Immunother. 61 2012 19 29
21. P.P. Peethambaram A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu Clin. Cancer Res. 15 2009 5937 5944
22. S.K. Pal A new age for vaccine therapy in renal cell carcinoma Cancer J. 19 2013 365 370
23. R.J. Kelly, and G. Giaccone Lung cancer vaccines Cancer J. 17 2011 302 308
24. S. Phuphanich Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma Cancer Immunol. Immunother. 62 2013 125 135
25. S.A. Perez AE37 peptide vaccination in prostate cancer: identification of biomarkers in the context of prognosis and prediction Cancer Immunol. Immunother. 2014 10.1007/s00262-014-1582-3
26. J. Tabernero First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement Cancer Discov. 3 2013 406 417
27. D. Strumberg Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors Int. J. Clin. Pharmacol. Ther. 50 2012 76 78
28. C. Qian Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling Clin. Cancer Res. 18 2012 4104 4113
29. T.L. Yuan, and L.C. Cantley PI3K pathway alterations in cancer: variations on a theme Oncogene 27 2008 5497 5510
30. M. Gaestel Protein kinases as small molecule inhibitor targets in inflammation Curr. Med. Chem. 14 2007 2214 2234
31. F. Namour Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects Drugs R D 12 2012 141 163
32. R. Westhovens Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial Ann. Rheum. Dis. 72 2013 741 744
33. M.E. Weinblatt Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial J. Rheumatol. 40 2013 369 378
34. E.F. Wagner, and A.R. Nebreda Signal integration by JNK and p38 MAPK pathways in cancer development Nat. Rev. Cancer 9 2009 537 549
35. S. Kumar p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases Nat. Rev. Drug Discov. 2 2003 717 726
36. J. Han A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells Science 265 1994 808 811
37. M.C. Genovese Inhibition of p38: has the fat lady sung? Arthritis Rheum. 60 2009 317 320
38. S. Muller, and S. Knapp Targeting kinases for the treatment of inflammatory diseases Expert Opin. Drug Discov. 5 2010 867 881
39. D.A. Lomas An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease J. Clin. Pharmacol. 52 2012 416 424
40. M. Elkhawad Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis JACC Cardiovasc. Imaging 5 2012 911 922
41. T. Ostenfeld Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain following peripheral nerve injury: a double-blind, placebo-controlled study Eur. J. Pain 17 2013 844 857
42. P. Dubreuil Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT PLoS ONE 4 2009 e7258
43. I. Marech Masitinib (AB1010), from canine tumor model to human clinical development: where we are? Crit. Rev. Oncol. Hematol. 91 2014 98 111
44. L. Frenzel, and O. Hermine Mast cells and inflammation Joint Bone Spine 80 2013 141 145
45. J. Tebib Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study Arthritis Res. Ther. 11 2009 R95
46. M. Humbert Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics Allergy 64 2009 1194 1201
47. P. Vermersch Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study BMC Neurol. 12 2012 36
48. F. Piette Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial Alzheimers Res. Ther. 3 2011 16
49. J.A. Whang, and B.Y. Chang Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis Drug Discov. Today 19 2014 1200 1204
50. M. Kanehisa KEGG for integration and interpretation of large-scale molecular data sets Nucleic Acids Res. 40 2012 D109 D114
51. L.K. Chico Targeting protein kinases in central nervous system disorders Nat. Rev. Drug Discov. 8 2009 892 909
52. C. Hooper The GSK3 hypothesis of Alzheimer's disease J. Neurochem. 104 2008 1433 1439
53. K. Leroy Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration Neuropathol. Appl. Neurobiol. 33 2007 43 55
54. E.M. Blalock Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses Proc. Natl. Acad. Sci. U.S.A. 101 2004 2173 2178
55. W. Noble Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo Proc. Natl. Acad. Sci. U.S.A. 102 2005 6990 6995
56. E. Rockenstein Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation J. Neurosci. 27 2007 1981 1991
57. T. del Ser Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study J. Alzheimers Dis. 33 2013 205 215
58. H. Mellor, and P.J. Parker The extended protein kinase C superfamily Biochem. J. 332 1998 281 292
59. M.K. Sun, and D.L. Alkon Activation of protein kinase C isozymes for the treatment of dementias Adv. Pharmacol. 64 2012 273 302
60. M. Kanehisa, and S. Goto KEGG: Kyoto encyclopedia of genes and genomes Nucleic Acids Res. 28 2000 27 30
61. A. Takashima Pretreatment with caerulein protects against memory impairment induced by protein kinase C inhibitors in the rat Peptides 12 1991 699 703
62. E.J. Weeber A role for the beta isoform of protein kinase C in fear conditioning J. Neurosci. 20 2000 5906 5914
63. M. Cordey Estrogen activates protein kinase C in neurons: role in neuroprotection J. Neurochem. 84 2003 1340 1348
64. A.P. Kozikowski New amide-bearing benzolactam-based protein kinase C modulators induce enhanced secretion of the amyloid precursor protein metabolite sAPPalpha J. Med. Chem. 46 2003 364 373
65. G. Wang Kinases and kinase signaling pathways: potential therapeutic targets in Parkinson's disease Prog. Neurobiol. 98 2012 207 221
66. O. Eberhardt, and J.B. Schulz Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson's disease Toxicol. Lett. 139 2003 135 151
67. L.H. Wang, and E.M. Johnson Jr Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease Neurology 71 2008 462 author reply 462-463
68. I. Martin Recent advances in the genetics of Parkinson's disease Annu. Rev. Genomics Hum. Genet. 12 2011 301 325
69. X. Deng Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2 Nat. Chem. Biol. 7 2011 203 205
70. N. Ramsden Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons ACS Chem. Biol. 6 2011 1021 1028
71. C. Manzoni Pathogenic Parkinson's disease mutations across the functional domains of LRRK2 alter the autophagic/lysosomal response to starvation Biochem. Biophys. Res. Commun. 441 2013 862 866
72. C. Manzoni Inhibition of LRRK2 kinase activity stimulates macroautophagy Biochim. Biophys. Acta 1833 2013 2900 2910
73. A.K. Vaishnaw A status report on RNAi therapeutics Silence 1 2010 14
74. J. Stjernschantz Studies on ocular inflammation and development of a prostaglandin analogue for glaucoma treatment Exp. Eye Res. 78 2004 759 766
75. S.K. Wang, and R.T. Chang An emerging treatment option for glaucoma: Rho kinase inhibitors Clin. Ophthalmol. 8 2014 883 890
76. R.D. Williams Ocular hypotensive effect of the Rho hinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension Am. J. Ophthalmol. 152 2011 834 841
77. T.J. van Haarlem Clinical development of AR-12286: assessing safety and ocular hypotensive efficacy in patients with elevated intraocular pressure and in normotensive volunteers Proc. Eur. Glaucoma Soc. Cong. Copehagen 2012 http://www.oic.it/∼egscopenaghen2012/posters/june20/P5.100/poster.pdf
78. J.M. Tarr Pathophysiology of diabetic retinopathy ISRN Ophthalmol. 2013 2013 343560
79. G. Mohammad, and R.A. Kowluru The role of Raf-1 kinase in diabetic retinopathy Expert Opin. Ther. Targets 15 2011 357 364
80. S.V. Joy Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications Ann. Pharmacother. 39 2005 1693 1699
81. M.J. Sheetz The effect of the oral PKC beta inhibitor ruboxistaurin on vision loss in two phase 3 studies Invest. Ophthalmol. Vis. Sci. 54 2013 1750 1757
82. US Food and Drug Administration Regranex (becaplermin) Gel 0.01% October 2008. Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) 2008 US Department of Health and Human Services http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm121631.htm
83. R. Mittermayr Fibrin biomatrix-conjugated platelet-derived growth factor AB accelerates wound healing in severe thermal injury J. Tissue Eng. Regen. Med. 2013 10.1002/term.1749
84. K. So Avotermin for scar improvement following scar revision surgery: a randomized, double-blind, within-patient, placebo-controlled, phase II clinical trial Plast Reconstr. Surg. 128 2011 163 172
85. D.B. Reichling, and J.D. Levine Critical role of nociceptor plasticity in chronic pain Trends Neurosci. 32 2009 611 618
86. J.E. Moodie A single-center, randomized, double-blind, active, and placebo-controlled study of KAI-1678, a novel PKC-epsilon inhibitor, in the treatment of acute postoperative orthopedic pain Pain Med. 14 2013 916 924
87. M.J. Cousins The safety and efficacy of KAI-1678- an inhibitor of epsilon protein kinase C (epsilonPKC)-versus lidocaine and placebo for the treatment of postherpetic neuralgia: a crossover study design Pain Med. 14 2013 533 540
88. L. McKelvey Nerve growth factor-mediated regulation of pain signalling and proposed new intervention strategies in clinical pain management J. Neurochem. 124 2013 276 289
89. M.F. Seidel, and N.E. Lane Control of arthritis pain with anti-nerve-growth factor: risk and benefit Curr. Rheumatol. Rep. 14 2012 583 588
90. Janssen Research Advisory Committee Briefing Book for 12 March 2012 Arthritis Advisory Committee Meeting: JNJ-42160443 (fulranumab) 2012 Janssen Research and Development
91. D. Holmes Anti-NGF painkillers back on track? Nat. Rev. Drug Discov. 11 2012 337 338
92. M.H. Ossipov Growth factors and neuropathic pain Curr. Pain Headache Rep. 15 2011 185 192
93. J.G. Nutt Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD Neurology 60 2003 69 73
94. N. Nikam Advances in stent technologies and their effect on clinical efficacy and safety Med. Devices (Auckl.) 7 2014 165 178
95. T. Palmerini Stent thrombosis with drug-eluting stents: is the paradigm shifting? J. Am. Coll. Cardiol. 62 2013 1915 1921
96. A. Hammer, and S. Steiner Gene therapy for therapeutic angiogenesis in peripheral arterial disease - a systematic review and meta-analysis of randomized, controlled trials Vasa 42 2013 331 339
97. M. Shimamura Gene therapy and cell-based therapies for therapeutic angiogenesis in peripheral artery disease Biomed. Res. Int. 2013 2013 186215
98. K. Inagaki Epsilon protein kinase C as a potential therapeutic target for the ischemic heart Cardiovasc. Res. 70 2006 222 230
99. E. Bates Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction Circulation 117 2008 886 896
100. S.Z. Fields Activin receptor antagonists for cancer-related anemia and bone disease Expert Opin. Investig. Drugs 22 2013 87 101
101. S. Lotinun A soluble activin receptor type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys Bone 46 2010 1082 1088
102. R.J. Fajardo Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis) Bone 46 2010 64 71
103. J. Ruckle Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women J. Bone Miner. Res. 24 2009 744 752
104. C.T. Dinh, and T.R. Van De Water Blocking pro-cell-death signal pathways to conserve hearing Audiol. Neurootol. 14 2009 383 392
105. M. Suckfuell Intratympanic treatment of acute acoustic trauma with a cell-permeable JNK ligand: a prospective randomized phase I/II study Acta Otolaryngol. 127 2007 938 942
106. R. Berggren Outlook for the next 5 years in drug innovation Nat. Rev. Drug Discov. 11 2012 435 436
107. M. Gerlinger Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N. Engl. J. Med. 366 2012 883 892
108. D. Shyr, and Q. Liu Next generation sequencing in cancer research and clinical application Biol. Proced. Online 15 2013 4